Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Int J Gynecol Pathol. 2016 Jul;35(4):289–300. doi: 10.1097/PGP.0000000000000243

Fig. 2. A combination of immunohistochemical and mutational analysis may aid in the distinction of sporadic high-grade TP53-mutant endometrial carcinomas of serous endometrial and FIGO grade 3 endometrioid histologic subtypes.

Fig. 2

Histologic features characteristic of MSI endometrial cancers or endometrial carcinomas harboring POLE hotspot mutations include enrichment in tumor-infiltrating lymphocytes and/or peri-tumoral lymphocytes, among others. *DNA MMR markers may be limited to MLH1 immunohistochemistry and/or MLH1 promoter methylation analysis. DNA MMR, DNA mismatch repair; IHC, immunohistochemistry; MSI, microsatellite instability.